A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimers Disease with a Stage Gate to Phase 2B (VIVAMIND)
Lay Description
Category
- IRB Number
- 20220043HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Regulatory Point of Contact
Sudha Seshadri
(210) 450-8437
Seshadri@uthscsa.edu
Principal Investigator
Sudha Seshadri